Skip to content

Hydrocolloid Dressing for Catheter Exit Site Care in Peritoneal Dialysis Patients

Study of Hydrocolloid Dressing for Peritoneal Dialysis Catheter Exit Site Care in Peritoneal Dialysis Patients - a Pilot Study

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05143164
Enrollment
60
Registered
2021-12-03
Start date
2022-03-11
Completion date
2024-12-30
Last updated
2024-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal Dialysis Catheter Exit Site Infection

Keywords

peritoneal dialysis, exit-site care, exit-site dressing

Brief summary

The study aims to examine the use of hydrocolloid dressing for catheter exit-site care in peritoneal dialysis patients. It is a pilot study, and participants will be randomized to either receiving weekly hydrocolloid dressing or daily topical gentamicin cream for exit-site care in peritoneal dialysis patients.

Detailed description

Peritoneal dialysis (PD) related infection is one of the main reasons for patients to discontinue PD therapy. Routine exit-site care is crucial for the prevention of infections, however, daily antibiotics use has been associated with the risk of developing drug-resistant bacteria. Moreover, the burden of daily exit-site care can lead to non-compliance with treatment. Hydrocolloid dressing has been used in the management of acute and chronic wounds and is required to change once weekly, but its use has not been examined in the exit-site wound in PD patients. The study primarily aims to examine PD-related infection (exit site infection or peritonitis rates) between patients using weekly hydrocolloid dressing (experimental group) and those using daily topical application of gentamicin (control group) for exit-site care in PD patients. Secondary aims include time to the first episode of PD-related infection, technique failure, PD infection-related hospitalization, and adverse events. The study will also assess the acceptability of dressing and quality of life between the two groups. A total of 60 adult peritoneal dialysis patients will be recruited for the study. Patients will be randomly assigned to either the experimental group or the control group. Participants will be followed up at the 4th, 12th, and 24th week of study. The acceptability of the dressing will be assessed using the treatment acceptability questionnaires. The quality of life will be assessed using the ED 5D-5L questionnaires.

Interventions

Duoderm Extra Thin hydrocolloid dressing will be used to cover the catheter exit-site of participants in the intervention group. The dressing will be changed every 7 days or early if the dressing is no longer adhesive.

DRUGGentamicin Sulfate, Topical

Application of gentamicin to exit site daily

Sponsors

Singapore General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All adult peritoneal dialysis patients (≥ 21 years old) and are followed up at Singapore General Hospital (SGH)

Exclusion criteria

* Patients who are unable to provide valid consent, patients who have known allergy to hydrocolloid dressing, patients who have peritoneal dialysis catheter exit site infection or peritonitis within the past 3 months, patients who have dialysate leak at PD catheter exit site, pregnant women, patients with life-expectancy of \< 1 year or patients who are currently involved in another study for peritoneal dialysis catheter exit site care.

Design outcomes

Primary

MeasureTime frameDescription
Peritoneal dialysis (PD)-related infection rate24 weeksPD-related infection (exit-site /tunnel infection or peritonitis) (episode per patient-year)

Secondary

MeasureTime frameDescription
Time to the first episode of exit-site/tunnel infection or peritonitis24 weeksTime to first episode of exit-site/tunnel infection or peritonitis (days)
Peritoneal dialysis infection-related hospitalization rate24 weeksHospitalization due to peritoneal dialysis-related infection (episode per patient-year)
Technique failure rate24 weeksTechnique failure is defined as transfer to hemodialysis for \>= 30 days (episode per patient-year)
Adverse events24 weeksAdverse events related to the dressing (local or systemic effects)
Quality of life score using ED 5D 5L questionnaireat 12th week of studyQuality of life score using ED 5D 5L questionnaire (numerical scores)
Treatment acceptabilityat 12th week of studyAcceptability of dressing will be measured by treatment acceptability questionnaire

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026